Third Milestone Payment Clause Samples

Third Milestone Payment. HMR shall pay to P&G ***** within seven (7) Business Days after the approval by the USFDA of an NDA or supplemental NDA for the Product with an indication for PMO.
View Source
Third Milestone Payment. Parent shall make a one-time Milestone Payment to the Company Securityholders equal to $50,000,000 (the “PMA Approval Milestone Payment”), to be paid in Parent Shares or cash (or any combination of Parent Shares or cash), such allocation in Parent’s sole and absolute discretion, in accordance with Section 2.16(c), on or prior to the 20th Business Day following the date upon which premarket approval has been received from the FDA to market and sell in the United States an Interventional System.
View Source
Third Milestone Payment. Upon [***] on or before [***], Terumo shall pay to OBIO, in consideration of the work that is required to be completed by ▇▇▇▇ in furtherance of achieving the fourth Milestone as set forth in Section 3.1(g) below within ten (10) Business Days of such [***], five million U.S. dollars ($5,000,000) (“Third Milestone Payment”). [***].
View Source
Third Milestone Payment. Subject to Section 2.8(e), upon FDA Approval (the “Third Milestone”), Acquiror shall issue to Target Stockholders the Third Milestone Stock Payment within thirty (30) days of achievement of the Third Milestone.
View Source
Third Milestone Payment. Upon Terumo filing with FDA for PMA for the Product for the Milestone Indication on or before March 30, 2024, Terumo shall pay to OBIO, in consideration of the work that is required to be completed by ▇▇▇▇ in furtherance of achieving the fourth Milestone as set forth in Section 3.1(g) below within ten (10) Business Days of such filing, [***] ($[***]) (“Third Milestone Payment”). If the filing is delayed as the result of a delay in the submission of the manufacturing module, then the Milestone date above mentioned as a condition to the third Milestone will be extended to the date that is sixty (60) days after the filing of the manufacturing module submission.
View Source
Third Milestone Payment. $[●] upon receipt by the Cumulus Entities of the distribution from the Escrow Account associated with the zoning approvals that meet the 960 MW Requirement, as defined in Schedule 1 of the Cumulus Purchase Agreement.
View Source
Third Milestone Payment. If the Third Milestone Condition is met, then the Purchaser shall pay a Milestone Payment within five (5) business days after the Annual Determination for calendar year 2022 shall have become binding on the parties as provided in Section 2.2.
View Source

Related to Third Milestone Payment

  • Milestone Payment The first time Net Sales in the Territory in a Royalty Period exceed [***] [***]

  • Milestone Event Milestone Payment [***] [***]

  • Milestone A principal event specified in the Contract Documents including the Material Completion and Occupancy Date and other events relating to an intermediate completion date or time.

  • Development Milestone Payments TriSalus shall pay (or cause to be paid) to Dynavax, in accordance with and subject to the terms of this Section 2.3, Section 2.4 and Section 6.4 (each such milestone, a “Development Milestone”, and each payment in respect thereof, a “Development Milestone Payment”): (i) Upon the successful completion by a Milestone Obligor after the Closing of a [**] study with respect to a Product using PEDD, a payment of [**] US Dollars ($[**]), with such Development Milestone Payment being payable only once (for purposes of the foregoing, successful completion means completion of such study in accordance with the plan for such study); (ii) For the first patient Dosed by a Milestone Obligor in each Phase 1 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iii) For the first patient Dosed by a Milestone Obligor in each Phase 2 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iv) For each Phase 2 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 2 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 2 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (v) For each Phase 3 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 3 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 3 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (vi) Upon receipt by a Milestone Obligor of each Regulatory Approval for any Product for any Indication in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (vii) Upon receipt by a Milestone Obligor for each Regulatory Approval of any Product for any Indication in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (viii) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vi) for receipt of such Regulatory Approval), regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; and (ix) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vii) for receipt of such Regulatory Approval), regardless ​ of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval.

  • Sales Milestone Payments Artiva shall make the following one-time, non-refundable and non-creditable sales milestone payments to GCLC when the aggregate annual Net Sales of Products in the Territory first reach the thresholds specified below. Artiva shall notify GCLC promptly of the achievement of each such sales threshold. Each sales milestone payment shall be made by Artiva within [***] days after the end of the calendar quarter in which such sales threshold is achieved. To the extent more than one sales threshold is reached in any given calendar year, then the applicable milestone payment for each such achievement shall be due and owing with respect to such calendar year. For clarification, the total milestone payments payable hereunder if all milestone events are achieved is [***].